R01GM067893 (APLIN, ANDREW E)Aug 1, 2004 - Mar 31, 2015 NIH
ADHESION AND ERK SIGNALING IN MELANOMA
Role: Principal Investigator |
|
R01CA125103 (APLIN, ANDREW E)Aug 1, 2008 - May 31, 2014 NIH
B-RAF Regulation of the Cell Cycle in Melanoma
Role: Principal Investigator |
|
R01CA160495 (APLIN, ANDREW ERIC)Jun 1, 2012 - Jul 31, 2023 NIH
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
Role: Principal Investigator |
|
R01CA182635 (APLIN, ANDREW ERIC)Jul 14, 2014 - May 31, 2025 NIH
Targeted therapies in cutaneous melanoma
Role: Principal Investigator |
|
R01CA196278 (APLIN, ANDREW E)Jun 24, 2015 - May 31, 2021 NIH
Mutant BRAF-regulated transcription factors in melanoma progression
Role: Principal Investigator |
|
T32CA236736 (LANGUINO, LUCIA R.)Sep 19, 2019 - Aug 31, 2024 NIH
Training Program in Cancer Biology
Role: Co-Principal Investigator |
|
R01CA253977 (APLIN, ANDREW ERIC)Sep 1, 2020 - May 31, 2025 NIH
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
Role: Principal Investigator |
|
R01CA257505 (GUTKIND, JORGE SILVIO)Apr 1, 2021 - Mar 31, 2026 NIH
Targeting Systems Vulnerabilities in the Gaq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
Role: Co-Principal Investigator |
|
R01CA256945 (APLIN, ANDREW ERIC)Jun 15, 2021 - May 31, 2026 NIH
Mechanisms of cell death in cutaneous melanoma
Role: Principal Investigator |